SCM
ZVRA icon

Sterling Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Sterling Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.6K Buy
877
+516
+143% +$5.74K ﹤0.01% 2104
2026
Q1 		$3.37K Sell
361
-5
-1% -$45 ﹤0.01% 2864
2025
Q4 		$3.28K Buy
366
+235
+179% +$2.22K ﹤0.01% 2991
2025
Q3 		$1.25K Hold
131
– – ﹤0.01% 3049
2025
Q2 		$1.15K Sell
131
-358
-73% -$2.9K ﹤0.01% 3039
2025
Q1 		$3.66K Sell
489
-208
-30% -$1.65K ﹤0.01% 2314
2024
Q4 		$5.81K Buy
697
+611
+710% +$5.21K ﹤0.01% 2394
2024
Q3 		$597 Buy
+86
New +$584 ﹤0.01% 2786

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sterling Capital Management's ZVRA Position: Q2 2026 in Review

Sterling Capital Management increased its Zevra Therapeutics (ZVRA) stake by 143% in Q2 2026, buying an estimated $5.74K and bringing the position to 877 shares worth $12.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2104.

Sterling Capital Management first reported a position in ZVRA in Q3 2024 and has held it in 8 quarters since. 158 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Sterling Capital Management held 877 shares of Zevra Therapeutics worth $12.6K as of Q2 2026.
  • Sterling Capital Management bought 516 Zevra Therapeutics shares in Q2 2026, an estimated $5.74K.
  • Zevra Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2104 holding.
  • Sterling Capital Management first reported a position in Zevra Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.